Company intelligence / Profile preview
Shanghai Biomabs Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Shanghai Biomabs Pharmaceuticals is a pioneer Chinese biopharma specializing in monoclonal antibody therapeutics and biosimilars. Its denosumab biosimilar has completed Phase III trials for osteoporosis, with other programs targeting ophthalmology and autoimmune diseases at various clinical stages. The company holds multiple patents for innovative antibody drugs domestically and internationally.
- Therapeutic areas
- OphthalmologyOncologyImmunologyRheumatologyWomen's Health
- Modalities
- Monoclonal antibodyFab fragmentBiosimilar
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shanghai Biomabs Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Biomabs Pharmaceuticals.